Exosome Cargos as Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma

Pharmaceutics. 2023 Sep 21;15(9):2365. doi: 10.3390/pharmaceutics15092365.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Due to the insidiousness of HCC onset and the lack of specific early-stage markers, the early diagnosis and treatment of HCC are still unsatisfactory, leading to a poor prognosis. Exosomes are a type of extracellular vesicle containing various components, which play an essential part in the development, progression, and metastasis of HCC. A large number of studies have demonstrated that exosomes could serve as novel biomarkers for the diagnosis of HCC. These diagnostic components mainly include proteins, microRNAs, long noncoding RNAs, and circular RNAs. The exosome biomarkers showed high sensitivity and high specificity in distinguishing HCC from health controls and other liver diseases, such as chronic HBV and liver cirrhosis. The expression of these biomarkers also exhibits correlations with various clinical factors such as tumor size, TMN stage, overall survival, and recurrence rate. In this review, we summarize the function of exosomes in the development of HCC and highlight their application as HCC biomarkers for diagnosis and prognosis prediction.

Keywords: biomarker; circular RNA; exosome; hepatocellular carcinoma; long noncoding RNA; microRNA.

Publication types

  • Review

Grants and funding

This study was supported by the Project of the Shanghai Municipal Health Commission. (20204Y0012): Natural Science Foundation of Shanghai (23ZR1438600), the National Natural Science Foundation of China (81972205), and the Project of Shanghai Key Clinical Specialties (shslczdzk05801).